Peer Cohort · Robust

Large-Cap Pharmaceuticals

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · Pharmaceuticals · 8 peers

· 8 not run

One action: refreshes every issuer report, pulls latest FMP pricing & revenue, recomputes cohort performance, then regenerates the cohort synthesis.

Peer Cohort Report

Large-Cap Pharmaceuticals — not yet synthesized

A cohort report needs ≥2 persisted issuer reports. Run the cohort fan-out above first — currently 0 ready.

Why these companies

Major pharmaceutical companies with diversified branded portfolios and substantial R&D pipelines. Peer economics center on patent cliff exposure, pipeline depth, and capital return through patent expirations.

Cohort performance · 90 days

Large-Cap Pharmaceuticals

…

Loading performance intelligence…

Leadership intelligence

… · last 90d

Loading leadership intelligence…

Members

8 issuers · scored first

ABBV

Covered

AbbVie Inc.

NYSE · $61B

AbbVie possesses a strong competitive moat primarily driven by its innovative dr…

BMY

Covered

Bristol-Myers Squibb

NYSE · $48B

Bristol-Myers Squibb is a biopharmaceutical company that discovers, develops, ma…

LLY

Covered

Eli Lilly and Company

NYSE · $65B

Eli Lilly and Company is a pharmaceutical company that discovers, develops, manu…

JNJ

Covered

Johnson & Johnson

NYSE · $94B

Johnson & Johnson has a wide moat due to its diversified healthcare portfolio sp…

MRK

Covered

Merck & Co.

NYSE · $65B

Merck's moat is primarily driven by its extensive patent portfolio covering a wi…

PFE

Covered

Pfizer Inc.

NYSE · $63B

Pfizer's moat is primarily driven by its extensive portfolio of patented drugs, …

VTRS

Covered

Viatris Inc.

NASDAQ · $14B

Viatris operates in the off-patent pharmaceutical sector, focusing on the produc…

ZTS

Covered

Zoetis Inc.

NYSE · $9B

Zoetis is the world leader in animal health, offering a comprehensive portfolio …